Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly.
暂无分享,去创建一个
Fabrizio Schifano | Ornella Corazza | Zoe Davey | Norbert Scherbaum | Paolo Deluca | Zsolt Demetrovics | M. Farré | Z. Demetrovics | M. Torrens | N. Scherbaum | O. Corazza | F. Schifano | P. Deluca | Magi Farre | Liv Flesland | Holger Siemann | Arvid Skutle | Marta Torrens | L. di Furia | Lucia Di Furia | Peer Van Der Kreeft | P. van der Kreeft | A. Skutle | H. Siemann | Z. Davey | Liv Flesland
[1] J. Gewirtz,et al. Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors , 2000, Neuropsychopharmacology.
[2] M. Farré,et al. Psychoactive drug or mystical incense? Overview of the online available information on Spice products , 2009 .
[3] E. sanders-Bush,et al. Agonist-Directed Signaling of Serotonin 5-HT2C Receptors: Differences Between Serotonin and Lysergic Acid Diethylamide (LSD) , 1999, Neuropsychopharmacology.
[4] Ornella Corazza. Le nuove potenzialità della prevenzione digitale in materia di nuove droghe : il ruolo del Recreational Drugs European Network , 2010 .
[5] D E Nichols,et al. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. , 1998, Journal of medicinal chemistry.
[6] A. Shulgin,et al. PIHKAL: A Chemical Love Story , 1991 .
[7] G. Aghajanian,et al. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. , 1996, The Journal of pharmacology and experimental therapeutics.
[8] J. Chambers,et al. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. , 2001, Journal of medicinal chemistry.
[9] D. Nelson,et al. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. , 1996, Journal of medicinal chemistry.
[10] R. Glennon,et al. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens , 2004, Psychopharmacology.
[11] E. sanders-Bush,et al. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. , 1988, The Journal of pharmacology and experimental therapeutics.
[12] M. Andreasen,et al. A fatal poisoning involving Bromo-Dragonfly. , 2009, Forensic science international.
[13] Fabrizio Schifano,et al. Drugs on the web; the Psychonaut 2002 EU project , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[14] J. Ramsey,et al. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY , 2009, Journal of Medical Toxicology.
[15] R. de la Torre,et al. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers. , 2008, Journal of pharmaceutical and biomedical analysis.
[16] F. Vollenweider. Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research , 1998, Pharmacopsychiatry.
[17] R. Glennon. Do classical hallucinogens act as 5-HT2 agonists or antagonists? , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[18] M. Perera. Near-Death Experiences: Exploring the Mind-Body Connection , 2010 .
[19] J. C. Winter,et al. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis , 1995, Psychopharmacology.